Wolfe Research has initiated coverage of BeOne Medicines AG (ONC) with an Outperform rating and a $340 price target, recognizing the company's robust development programs in biotech. This positive outlook is primarily driven by the success of Brukinsa, identified as a leading hematology asset, and a promising drug pipeline. Despite recent downgrades from other firms due to concerns about fixed-duration therapies, Wolfe Research views these concerns as potentially overblown, presenting a buying opportunity. The company also recently received orphan drug designation for its hepatocellular carcinoma treatment, further bolstering its therapeutic portfolio.

RBC Capital has adjusted its price target for Bicycle Therapeutics (BCYC) downwards from $11 to $7, while Oppenheimer also reduced its target from $44 to $36. These changes follow Bicycle Therapeutics' decision to de-prioritize its drug candidate, zelenectide, and restructure operations, including workforce reductions, to focus on other pipeline programs like BT5528 and radio-conjugates. The company reported better-than-expected Q4 earnings and revenue, driven by collaboration revenue recognition.

As warmer days approach, sky blue sneakers are emerging as a key footwear trend, offering a blend of casual elegance and versatility. Seen on social media and off-duty models, these pale and icy blue hues complement various spring palettes and styles, from athletic designs to luxurious satin finishes. Discover how these serene shades are becoming a must-have for adding a touch of personality to any spring ensemble.

Navigating the unspoken rules of bridal shower fashion can be tricky, but this guide provides clear advice on what to wear and what to avoid. Whether the event is a garden party or a rooftop brunch, selecting an ensemble that feels both elegant and appropriate is key. Discover seven curated party-ready dresses and matching sets designed to help you maintain your reputation as the most fashionably dressed in your social circle.